S&P/ASX 200 Index (ASX: XJO) mining shares experienced an outstanding year in FY26.

The ASX 200 materials sector, dominated by miners, was the best of the 11 market sectors, rising 47% and returning 52% in total.

The S&P/ASX 300 Metals & Mining Index (ASX: XMM), which captures more of the explorers than the ASX 200, did even better.  

ASX 300 mining shares rose 53%, and delivered a total return of 59%.

Australia is in the midst of a new mining boom driven by five key elements.

Many commodities rose in value in FY26, which boosted the earnings of the 5 best ASX 200 mining shares of the year.

Here, we look at three ASX mining shares that brokers recommend buying now for FY27.

BHP Group Ltd (ASX: BHP)

The BHP share price is up 2.6% to $58.35 today, and up 52% over 12 months.

BHP was one of the best performers for capital growth amongst the ASX 200 large-cap shares last year.

Blake Halligan from Catapult Wealth explains his buy rating on BHP shares:  

The global miner holds dominant positions in iron ore and copper and is leveraged to increasing demand during the energy transition.

Despite the Jansen impairment and the risk of industrial action at iron ore operations in the Pilbara region of Western Australia, near term earnings momentum remains strong.

The balance sheet remains robust with low net debt, while a recent dividend yield above 3 per cent adds income appeal.

Read more about what the experts anticipate for BHP shares over the next 12 months.

Nickel Industries Ltd (ASX: NIC)

The Nickel Industries share price is 89 cents, up 2.3% today and up 21% over 12 months.

Bell Potter has a buy rating with a 12-month price target of $1.55 on this ASX 300 nickel share.

This implies potential capital growth of almost 75% over the next 12 months.

The broker said:

NIC offers nickel price leverage and diversified margin exposure across an integrated value chain.

The HPAL expansion transactions will further balance NIC’s earnings into downstream higher-margin operations and preserve earnings through the nickel price cycle.

Maronan Metals Ltd (ASX: MMA)

The Maronan Metals share price is 43 cents, down 1.2% today and up 93% over 12 months.

Maronan is developing a silver-lead and copper-gold deposit in Queensland’s Cloncurry region.

The mine is one of Australia’s largest undeveloped silver-lead and copper-gold deposits.

Morgans initiated coverage on this ASX silver share with a speculative buy call and a 66-cent target this month.

This implies a potential 53% upside over the next 12 months.

The broker said:

The wholly-owned Maronan Mineral Development Lease (MDL 2028) was approved in September 2025, after the Preliminary Economic Assessment (PEA) evaluated a 10-year underground mine life based on 22% of the total resource.

The resource to JORC Code (2012) standards contains 122Moz silver, 2Mt lead, 271kt copper and 0.76Moz gold, with yearly production 5.4Moz silver equivalent (AgEq) at an all-in sustaining cost (AISC) of A$30.18/oz (~US$20/oz) AgEq.

While the PEA is robust, MMA is yet to deliver a feasibility study, secure development finance, receive grant of a Mining Lease, and commence the path from construction to production.

With 40-45% exposure to silver and 20-25% to lead, commodity prices are also the key to the level of profitability.

The post 3 ASX mining shares to buy now: experts appeared first on The Motley Fool Australia.

More reading

• ASX 200 snaps its losing streak as miners and banks rally
• 9 ASX 200 shares with reiterated buy calls this week
• Here’s what brokers tip for BHP shares over the next 12 months
• The bull and bear case for CBA and BHP shares
• Which ASX 200 sectors paid the highest dividend yields in FY26?

Motley Fool contributor Bronwyn Allen has positions in BHP Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Few ASX stocks have given investors a more brutal ride than WiseTech Global Ltd (ASX: WTC) this year.

The WiseTech share price has fallen 50% since the start of 2026 and is now trading a long way below its 52-week high of $121.31.

At the time of writing, the stock is down another 1.21% on Friday to $34.21, taking its monthly decline to around 10%.

However, WiseTech has recovered from its low of $28.76 on 23 June. The stock has posted several large daily gains over the past few weeks, although those rallies have often been followed by more selling.

Investors are now weighing comments from management about one of the company’s largest customers, while trying to work out whether the recent low has finally marked the bottom.

Here’s the latest.

WiseTech tries to ease customer concerns

According to The Australian, WiseTech Chief Executive Zubin Appoo is trying to settle concerns about Danish logistics group DSV.

DSV completed its 14.3-billion-euro takeover of DB Schenker in April 2025, creating one of the world’s largest transport and logistics companies.

The issue that’s taking centre stage is that DSV could eventually replace WiseTech’s CargoWise software with Tango, the system acquired through DB Schenker.

However, Appoo said DSV remains an active WiseTech customer and continues to increase its use of CargoWise.

He said:

DSV remains an active WiseTech customer. CargoWise transaction volumes with DSV have grown by around 20 per cent in the last six months.

Take note, the number of DSV users on CargoWise has reportedly increased by around 3% over the same period.

Appoo recently met with DSV Chief Executive Jens Lund and said both companies remain committed to their long-term relationship. DSV’s current contract runs until September 2028.

WiseTech pointed out that large CargoWise installations can take between 5 and 7 years to complete. And that customer attrition has remained below 1% a year over the past 14 years.

Investors are not convinced yet

Despite the reassurance, analysts at Citi still see the potential DSV migration as a risk.

The broker has warned about the issue since February and again highlighted “DSV migration headwinds” this week.

Citi has reportedly reduced its FY28 CargoWise revenue growth forecast to 7%, removing around $80 million from its previous estimate.

This means that the downgrade shows Citi is allowing for some impact, even though DSV hasn’t confirmed it will leave CargoWise.

Has the WiseTech share price bottomed?

There are signs that buyers are stepping in around the low-$30 mark, but the stock is still moving around a lot.

WiseTech shares jumped 14.26% on 24 June, then rose another 7.31% and 5.65% earlier this week. The stock gave back 7.28% on Wednesday.

Keep in mind, the business is still profitable, and CargoWise is widely used across the logistics industry.

And DSV hasn’t confirmed any plans to leave the platform either.

The share price could remain under pressure in the short term, but a stronger-than-expected August result could help shift the mood.

The post Has the WiseTech share price finally hit the bottom after crashing 50%? appeared first on The Motley Fool Australia.

More reading

• 9 ASX 200 shares with reiterated buy calls this week
• Two ASX tech shares hinge on rebuilding trust and growth. Here’s how they can turn around
• How low could WiseTech shares go?
• Why the WiseTech share price is sinking 7% today
• 2 ASX shares tipped to grow 50% or more in the next 12 months

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

4DMedical Ltd (ASX: 4DX) shares took a breather during Friday’s session, edging 1% higher to $4.10.

The healthcare technology company has pulled back around 12% over the past six months and now trades roughly 46% below the record high it reached in April.

However, the longer-term picture looks very different. This ASX healthcare share is still up an astonishing 1,636% over the past 12 months. Yes, that’s more than sixteen-fold in just one year.

So, after such an extraordinary run, could 4DMedical shares eventually reclaim their all-time high?

Why investors have become so bullish

The biggest catalyst behind the remarkable rise of 4DMedical shares has been growing confidence in its commercial prospects.

The company has developed proprietary respiratory imaging technology that produces four-dimensional lung scans, giving doctors significantly more information than traditional imaging methods. The technology has applications across chronic respiratory diseases, lung cancer, and surgical planning.

Importantly, management has shifted its focus from proving the technology to commercialising it.

US growth and AI investments

Over the past year, 4DMedical has secured several significant contracts and partnerships across the US. Recently, the business signed a major agreement with SimonMed, helping expand its CT:VQ lung imaging technology across the US.

Management believes the deal could lift its addressable market to around US$3 billion with major healthcare providers and government agencies. These agreements have strengthened investor confidence that revenue growth can accelerate as adoption increases.

The company has also continued investing in artificial intelligence capabilities to expand the usefulness of its imaging platform and create additional opportunities within respiratory care.

The path back to record highs

For 4DMedical shares to revisit their April peak, investors will likely need further evidence that commercial momentum is translating into sustainable financial results.

Like many emerging healthcare technology companies, 4DMedical remains focused on scaling its business rather than generating large profits today. That means investors are placing significant value on its future growth potential.

Continued contract wins, increasing scan volumes, expanding recurring revenue, and progress in the US healthcare market could all help support a higher valuation over time.

Heavy investments in research

Despite its enormous gains, 4DMedical remains a higher-risk investment.

Commercialising new medical technology can take longer than expected. Particularly, when healthcare providers require clinical validation and budget approvals before adopting new products.

The company also faces competition from established medical imaging businesses and must continue investing heavily in research, product development, and sales to maintain its competitive advantage.

As a high-growth healthcare stock, 4DMedical shares are also likely to remain volatile. Even positive companies can experience large share price swings as investor sentiment shifts.

The post Up 1,636%, but can 4DMedical shares reclaim their record high? appeared first on The Motley Fool Australia.

More reading

• Which ASX 200 sectors paid the highest dividend yields in FY26?
• This red-hot ASX healthcare share hit a speed bump. What next?
• 13 ASX 200 shares that doubled in value in FY26
• 2 ASX 200 healthcare shares to buy after sector rebounds 23% in a month
• These are the 10 most shorted ASX shares

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.